Your session is about to expire
← Back to Search
Virus Therapy
Patients with a living donor for Lung Cancer (RIM Trial)
Phase 1
Waitlist Available
Led By Razvan B Diaconescu, MD
Research Sponsored by Hopital du Sacre-Coeur de Montreal
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months
Awards & highlights
RIM Trial Summary
This trial will test whether combining low-dose radiotherapy with allogeneic immune cells and cyclophosphamide is safe and feasible in patients with advanced cancer.
Eligible Conditions
- Lung Cancer
RIM Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Incidence of treatment-related adverse events
Secondary outcome measures
Immune responses - T cell infiltration
Immune responses - Tumor cell phenotype
Immune responses - origin of tumor infiltrating T cells
+1 moreRIM Trial Design
2Treatment groups
Experimental Treatment
Group I: Patients with a living donorExperimental Treatment1 Intervention
Radiation + PBMC
Group II: Patients with a UCB donorExperimental Treatment1 Intervention
Radiation + UCB
Find a Location
Who is running the clinical trial?
Hopital du Sacre-Coeur de MontrealLead Sponsor
51 Previous Clinical Trials
12,245 Total Patients Enrolled
Maisonneuve-Rosemont HospitalOTHER
99 Previous Clinical Trials
36,299 Total Patients Enrolled
Razvan B Diaconescu, MDPrincipal InvestigatorCIUSSS du Nord-de-l'Île-de-Montréal - Hôpital du Sacré-Cœur de Montréal
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What potential hazards can manifest in those undergoing a living donor transplant?
"Based on the limited data available, our team at Power gauged the safety of patients with a living donor as a 1. This is because this trial is still in its initial phase, meaning there are no substantial studies that evidence efficacy or validate safety."
Answered by AI
Is enrollment still available for this research endeavor?
"Unfortunately, the trial is not seeking participants at this time. It was first posted on April 20th 2018 and last edited February 14th 2021. However, there are 1629 other medical trials that need members currently."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger